ZIVO Bioscience, Inc. (ZIVO)
USD 16.02
(-15.68%)
USD 16.02
(-15.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.27 Million USD | -16.69% |
| 2022 | 8.73 Million USD | -3.54% |
| 2021 | 9.05 Million USD | 5.56% |
| 2020 | 8.57 Million USD | 2.67% |
| 2019 | 8.35 Million USD | 36.24% |
| 2018 | 6.13 Million USD | -3.15% |
| 2017 | 6.33 Million USD | 81.36% |
| 2016 | 3.49 Million USD | 14.21% |
| 2015 | 3.05 Million USD | -18.76% |
| 2014 | 3.76 Million USD | 20.95% |
| 2013 | 3.11 Million USD | 49.49% |
| 2012 | 2.08 Million USD | 9.28% |
| 2011 | 1.9 Million USD | -53.47% |
| 2010 | 4.09 Million USD | 53.34% |
| 2009 | 2.66 Million USD | 112.31% |
| 2008 | 1.25 Million USD | -43.59% |
| 2007 | 2.22 Million USD | -42.63% |
| 2006 | 3.88 Million USD | 25.93% |
| 2005 | 3.08 Million USD | -19.51% |
| 2004 | 3.83 Million USD | 608.7% |
| 2003 | 540.63 Thousand USD | 15661.92% |
| 2002 | 3430.00 USD | 66.91% |
| 2001 | 2055.00 USD | -43.09% |
| 2000 | 3611.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 8.22 Million USD | 538.78% |
| 2024 Q1 | 1.28 Million USD | -32.22% |
| 2023 Q1 | 1.97 Million USD | -25.31% |
| 2023 FY | 7.27 Million USD | -16.69% |
| 2023 Q4 | 1.9 Million USD | 20.56% |
| 2023 Q3 | 1.57 Million USD | -13.72% |
| 2023 Q2 | 1.82 Million USD | -7.26% |
| 2022 Q4 | 2.63 Million USD | 31.88% |
| 2022 FY | 8.73 Million USD | -3.54% |
| 2022 Q2 | 2.06 Million USD | 2.03% |
| 2022 Q3 | 2 Million USD | -3.26% |
| 2022 Q1 | 2.02 Million USD | -35.94% |
| 2021 Q3 | 2.05 Million USD | 17.52% |
| 2021 Q1 | 2.08 Million USD | 18.72% |
| 2021 Q4 | 3.16 Million USD | 53.88% |
| 2021 Q2 | 1.74 Million USD | -16.04% |
| 2021 FY | 9.05 Million USD | 5.56% |
| 2020 Q3 | 3.36 Million USD | 226.68% |
| 2020 Q2 | 1.02 Million USD | -57.55% |
| 2020 FY | 8.57 Million USD | 2.67% |
| 2020 Q1 | 2.42 Million USD | -35.7% |
| 2020 Q4 | 1.75 Million USD | -47.84% |
| 2019 Q4 | 3.77 Million USD | 139.72% |
| 2019 Q1 | 967.85 Thousand USD | -40.16% |
| 2019 Q2 | 2.03 Million USD | 110.49% |
| 2019 FY | 8.35 Million USD | 36.24% |
| 2019 Q3 | 1.57 Million USD | -22.74% |
| 2018 Q1 | 1.68 Million USD | -35.18% |
| 2018 Q3 | 1.49 Million USD | 11.96% |
| 2018 FY | 6.13 Million USD | -3.15% |
| 2018 Q4 | 1.61 Million USD | 8.19% |
| 2018 Q2 | 1.33 Million USD | -20.68% |
| 2017 FY | 6.33 Million USD | 81.36% |
| 2017 Q2 | 881.44 Thousand USD | 11.4% |
| 2017 Q1 | 791.27 Thousand USD | 23.12% |
| 2017 Q4 | 2.59 Million USD | 26.02% |
| 2017 Q3 | 2.06 Million USD | 133.78% |
| 2016 FY | 3.49 Million USD | 14.21% |
| 2016 Q4 | 642.65 Thousand USD | -5.09% |
| 2016 Q3 | 677.11 Thousand USD | -55.75% |
| 2016 Q2 | 1.53 Million USD | 138.87% |
| 2016 Q1 | 640.55 Thousand USD | -3.49% |
| 2015 Q2 | 1.04 Million USD | 85.23% |
| 2015 FY | 3.05 Million USD | -18.76% |
| 2015 Q4 | 663.74 Thousand USD | -15.8% |
| 2015 Q3 | 788.3 Thousand USD | -24.33% |
| 2015 Q1 | 562.44 Thousand USD | -48.21% |
| 2014 Q2 | 800.71 Thousand USD | 2.82% |
| 2014 Q1 | 778.75 Thousand USD | -3.18% |
| 2014 FY | 3.76 Million USD | 20.95% |
| 2014 Q4 | 1.08 Million USD | -0.96% |
| 2014 Q3 | 1.09 Million USD | 36.93% |
| 2013 Q4 | 804.31 Thousand USD | -9.44% |
| 2013 Q3 | 888.15 Thousand USD | 0.65% |
| 2013 Q2 | 882.4 Thousand USD | 64.83% |
| 2013 FY | 3.11 Million USD | 49.49% |
| 2013 Q1 | 535.33 Thousand USD | 22.13% |
| 2012 Q4 | 438.32 Thousand USD | -32.9% |
| 2012 Q2 | 481.78 Thousand USD | -5.01% |
| 2012 Q3 | 653.26 Thousand USD | 35.59% |
| 2012 FY | 2.08 Million USD | 9.28% |
| 2012 Q1 | 507.21 Thousand USD | -45.27% |
| 2011 Q4 | 926.74 Thousand USD | 214.16% |
| 2011 Q1 | 424.68 Thousand USD | -42.73% |
| 2011 Q2 | 257.51 Thousand USD | -39.36% |
| 2011 Q3 | 294.99 Thousand USD | 14.55% |
| 2011 FY | 1.9 Million USD | -53.47% |
| 2010 Q1 | 973.35 Thousand USD | 35.91% |
| 2010 Q2 | 1.82 Million USD | 87.01% |
| 2010 Q3 | 556.67 Thousand USD | -69.42% |
| 2010 Q4 | 741.6 Thousand USD | 33.22% |
| 2010 FY | 4.09 Million USD | 53.34% |
| 2009 Q2 | 334.06 Thousand USD | -37.65% |
| 2009 Q4 | 716.19 Thousand USD | -33.84% |
| 2009 Q3 | 1.08 Million USD | 224.07% |
| 2009 FY | 2.66 Million USD | 112.31% |
| 2009 Q1 | 535.77 Thousand USD | 135.54% |
| 2008 Q3 | 275.8 Thousand USD | -41.34% |
| 2008 Q1 | 283.52 Thousand USD | -27.55% |
| 2008 FY | 1.25 Million USD | -43.59% |
| 2008 Q2 | 470.12 Thousand USD | 65.82% |
| 2008 Q4 | 227.46 Thousand USD | -17.53% |
| 2007 Q4 | 391.35 Thousand USD | -44.79% |
| 2007 Q1 | 657.13 Thousand USD | -38.67% |
| 2007 Q2 | 470.75 Thousand USD | -28.36% |
| 2007 Q3 | 708.84 Thousand USD | 50.58% |
| 2007 FY | 2.22 Million USD | -42.63% |
| 2006 FY | 3.88 Million USD | 25.93% |
| 2006 Q2 | 1.2 Million USD | 24.09% |
| 2006 Q3 | 633.01 Thousand USD | -47.54% |
| 2006 Q4 | 1.07 Million USD | 69.27% |
| 2006 Q1 | 972.33 Thousand USD | 6.44% |
| 2005 Q2 | 319.29 Thousand USD | -5.13% |
| 2005 Q4 | 913.54 Thousand USD | -42.88% |
| 2005 Q1 | 336.56 Thousand USD | -39.45% |
| 2005 FY | 3.08 Million USD | -19.51% |
| 2005 Q3 | 1.59 Million USD | 400.88% |
| 2004 Q2 | 721.44 Thousand USD | -55.24% |
| 2004 FY | 3.83 Million USD | 608.7% |
| 2004 Q4 | 555.84 Thousand USD | -41.2% |
| 2004 Q1 | 1.61 Million USD | 199.79% |
| 2004 Q3 | 945.29 Thousand USD | 31.03% |
| 2003 Q2 | 561.00 USD | -70.4% |
| 2003 FY | 540.63 Thousand USD | 15661.92% |
| 2003 Q4 | 537.61 Thousand USD | 95731.91% |
| 2003 Q1 | 1895.00 USD | 237.79% |
| 2003 Q3 | 561.00 USD | 0.0% |
| 2002 Q2 | 597.00 USD | -63.46% |
| 2002 Q1 | 1634.00 USD | 166.56% |
| 2002 FY | 3430.00 USD | 66.91% |
| 2002 Q4 | 561.00 USD | -12.07% |
| 2002 Q3 | 638.00 USD | 6.87% |
| 2001 Q2 | 620.00 USD | 196.65% |
| 2001 Q4 | 613.00 USD | 0.0% |
| 2001 FY | 2055.00 USD | -43.09% |
| 2001 Q3 | 613.00 USD | -1.13% |
| 2001 Q1 | 209.00 USD | -90.62% |
| 2000 Q4 | 2228.00 USD | 257.62% |
| 2000 Q2 | 460.00 USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | 3611.00 USD | 0.0% |
| 2000 Q3 | 623.00 USD | 35.43% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | 15.23 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -1000.162% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 21.508% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 75.746% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 89.166% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 54.083% |
| Better Therapeutics, Inc. | 38.26 Million USD | 80.987% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 82.121% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 41.299% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 78.505% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 78.865% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 93.293% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -632.731% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 77.678% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 84.506% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -498.888% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 63.516% |
| Molecular Templates, Inc. | 63.09 Million USD | 88.47% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 47.783% |
| NexImmune, Inc. | 28.16 Million USD | 74.174% |
| Orgenesis Inc. | 45.75 Million USD | 84.102% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 71.636% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -9808.769% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 54.943% |
| Scopus BioPharma Inc. | 11.71 Million USD | 37.903% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 98.197% |
| Statera Biopharma, Inc. | 28.82 Million USD | 74.767% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 61.569% |
| Trevena, Inc. | 38.41 Million USD | 81.062% |
| Vaxxinity, Inc. | 56.05 Million USD | 87.021% |
| Vaccinex, Inc. | 23.45 Million USD | 68.985% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -594.821% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 85.65% |